Study on Chemotherapy and Radiation with Pembrolizumab, Followed by Pembrolizumab and Olaparib, for Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with Small Cell Lung Cancer (SCLC) based on lab tests.
• Cancer is in a limited stage (Stage I-III) and can be treated with radiation.
• No signs of cancer spreading to other parts of the body.
• At least one tumor that can be measured by scans.
• No previous treatment for LS-SCLC.
• Not expected to need surgery to remove the tumor during the study.
• Must provide a tumor sample before starting treatment.
• Good overall health with a performance status score of 0 or 1.
• Expected to live at least 6 more months.
• Healthy organ function.
• Participants of childbearing potential must use birth control during and after treatment.
• Must be 18 years or older.
• Men must not donate sperm during and after treatment.
• Women must not breastfeed during and after treatment for specified periods.

Exclusion Criteria

• History or signs of certain blood disorders like myelodysplastic syndrome or acute myeloid leukemia.
• Previous treatment with specific immune therapies or PARP inhibitors like olaparib.
• Major surgery within 4 weeks before starting the study (except for minor procedures like placing a catheter).
• Participation in another clinical trial within 4 weeks before starting this study.
• Immune system deficiencies or use of high-dose steroids or other immune-suppressing drugs recently.
• Another active cancer needing treatment in the past 5 years, except for certain skin or bladder cancers.
• Severe allergies to study drugs or their ingredients.
• Active autoimmune diseases needing treatment in the past 2 years.
• History of lung diseases requiring steroids.
• Active infections needing treatment.
• Known HIV or active Hepatitis B or C infections.